🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million infections per year. Especially elevated rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The World Health Organization has listed it as a "high-priority threat". A tracking program showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Approval

One new antibiotic, alternatively called a brand name, was approved by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in close succession. This treatment, which is also used to treat UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This milestone marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

According to findings released by a prominent scientific publication, zoliflodacin eradicated over nine in ten of uncomplicated infections. This places it at an equal footing with the current standard treatment, which involves an injection and a pill. The research enrolled hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have voiced hope. Having a one-pill regimen like this is hailed as a "revolutionary step" for gonorrhoea control. This is considered crucial to lessen the impact of the illness for patients and to prevent the spread of untreatable gonorrhoea globally.